ARS Pharmaceuticals, Inc.
SPRY
Positions held
Your positionsSPRY isn't in your positions.
Add it to see shares, cost, and P&L here.
Fundamentals
| Market cap | $453.48M | Enterprise value | $481.24M | Trailing P/E | — | Forward P/E | -5.09 |
| PEG | — | Price / book | 36.19 | Beta | 1.08 | Dividend yield | 0.00% |
| Revenue growth | 114.2% | Earnings growth | — | Gross margin | 58.3% | Operating margin | -1.8% |
| Profit margin | -1.8% | ROE | -2.1% | ROA | -48.0% | Debt / equity | 13.72 |
| Current ratio | 3.48 | Free cash flow | -$117.70M | Analyst recommendation | none | Mean target | $22.50 |
| 52w high | $13.15 | 52w low | $3.99 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $33.7M | $22.7M | $28.1M | $32.5M | $15.7M | — |
| Op margin | -182.6% | -265.2% | -147.6% | -163.7% | -302.9% | — |
| Net income | -$62.3M | -$60.6M | -$41.3M | -$51.2M | -$44.9M | — |
| Gross margin | 61.8% | 72.3% | 78.1% | 74.8% | 68.3% | — |
| Gross profit | $20.8M | $16.4M | $21.9M | $24.3M | $10.7M | — |
| Operating income | -$61.5M | -$60.1M | -$41.5M | -$53.2M | -$47.6M | — |
- Revenue +48% vs prior quarter ($34M vs $23M).
- Gross margin 61.8% (was 72.3% prior quarter).
- Operating margin expanded to -182.6%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $84.3M | $89.1M | $0.0M | $1.3M | — |
| Op margin | -212.9% | -3.5% | -225066.7% | -2698.8% | — |
| Net income | -$171M | $8.0M | -$54.4M | -$34.7M | — |
| Gross margin | 75.8% | 98.9% | 100.0% | — | — |
| Gross profit | $63.9M | $88.2M | $0.0M | — | — |
| Operating income | -$179M | -$3.1M | -$67.5M | -$35.5M | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-09-01 · ARS Pharmaceuticals to Participate in Upcoming Investor Conferences
2026-08-21 · ARS Pharma (SPRY) Cuts Spending As It Chases Neffy Market Share
2026-08-20 · Can ARS Pharmaceuticals, Inc. (SPRY) Climb 297.02% to Reach the Level Wall Street Analysts Expect?
2026-08-14 · ARS Pharmaceuticals, Inc. Q2 2026 Earnings Call Summary
2026-08-14 · ARS Pharmaceuticals Inc (SPRY) (Q2 2026) Earnings Call Highlights: Market Share Doubles to 5% ...
2026-08-14 · ARS Pharmaceuticals Q2 Earnings Call Highlights
2026-08-13 · ARS Pharmaceuticals Q2 Net Loss Widens, Revenue Rises
2026-08-13 · ARS Pharmaceuticals, Inc. (SPRY) Reports Q2 Loss, Tops Revenue Estimates
2026-08-12 · What To Expect From ARS Pharmaceuticals Inc (SPRY) Q2 2026 Earnings
2026-08-06 · Cronos Group (CRON) Surpasses Q2 Earnings and Revenue Estimates
Price (daily)
Full chart · RSI · MACD · patterns